The further application of this approach for the characterization of CD4+ T cells specific for ESO and other tumor antigens in the circulation and at tumor sites of cancer patients, both along the natural course of the disease and during therapy, will likely contribute to significantly further our understanding of their roles and contribution in immunity to cancer. Here, CD4 is linked to neoplasm.